What question did this study set out to answer?

To describe SF3B1-mutated MDS patients and assess prognostic differences between variants.

December 8, 2025BloodOpen Access

Clinical characteristics and molecular profiling of SF3B1-mutated myelodysplastic syndrome (MDS) in a real-world practice

View Full Paper

Ask AI

Bookmark

Authors

Clinical characteristics and outcomes in SF3B1-mutated MDS patients reveal implications for treatment strategies.

To describe SF3B1-mutated MDS patients and assess prognostic differences between variants.
Retrospective identification of MDS patients with SF3B1 variants via next-generation sequencing.
Extraction and amplification of genomic DNA and RNA from bone marrow or blood samples.
Evaluation of hematological parameters, mutation profiles, and disease outcomes.
Nineteen MDS patients with SF3B1 variants were identified.
Ten variants of SF3B1 were found, with K7000E being most prevalent.
Patients with more co-mutations had less favorable IPSS-M scores and worse outcomes.

Wang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Clinical characteristics and outcomes in SF3B1-mutated MDS patients reveal implications for treatment strategies.

To describe SF3B1-mutated MDS patients and assess prognostic differences between variants.
Retrospective identification of MDS patients with SF3B1 variants via next-generation sequencing.
Extraction and amplification of genomic DNA and RNA from bone marrow or blood samples.
Evaluation of hematological parameters, mutation profiles, and disease outcomes.
Nineteen MDS patients with SF3B1 variants were identified.
Ten variants of SF3B1 were found, with K7000E being most prevalent.
Patients with more co-mutations had less favorable IPSS-M scores and worse outcomes.

Wang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark